NEJM 新英格兰医学杂志· Paul M Ridker A. Michael Lincoff Nikolaus Marx Ann Marie Navar Naveed Sattar Katherine R. Tuttle Matthew Budoff Morten Böttcher Matthew A. Cavender Robin P. Choudhury Jan H. Cornel Grzegorz Gajos Issei Komuro K.M.K. Reddy Parvathareddy Roberto Pontremoli José Francisco Kerr Saraiva Iana I. Simova Lance A. Sloan Alejandro López-Suárez Yi-Da Tang Lale Tokgözoğlu Nqoba Tsabedze Konstantinos Tsioufis Subodh Verma Mathias Vrolix Andreas Andersen Florian M.M. Baeres Kathrine Ekström Mads D.M. Engelmann Sofia Gerward G. Kees Hovingh Anders Hvelplund and Vlado Perkovicthe ZEUS Investigators*·· 13 天前AI 评分15
Ziltivekimab 用于动脉粥样硬化疾病临床试验结果公布
Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease
AI 导读
Ziltivekimab 用于动脉粥样硬化疾病的 III 期临床试验结果在 NEJM 发表,显示该药在降低心血管事件风险方面具有统计学显著性差异,但具体疗效和安全性仍需进一步验证。
来源:NEJM 新英格兰医学杂志 · nejm.org